Now, let's consider what's ahead for Amtagvi specifically. Iovance prepared for this moment last year by acquiring worldwide rights to cancer drug Proleukin from Clinigen. Amtagvi involves a conditioning phase that clears out existing lymphocytes and readies the body for treatment -- and this initial phase includes a course of Proleukin. Iovance's acquisition of this drug may help boost its earnings potential since Proleukin is an integral part of the TIL process.